The Family Physician’s Unique Role in Heart Failure Management

Grace L. Chua

doi:10.58931/cpct.2024.2335

Authors

Grace L. Chua, MD, FRCPC, FACC Cardiologist, Mackenzie Health, Maple, Ontario, Canada

DOI:

https://doi.org/10.58931/cpct.2024.2335

Abstract

Heart failure (HF) is an epidemic with a prognosis that is worse than some cancers. Prevention, early diagnosis, coordination, and implementation of guideline-directed medical therapy (GDMT) are imperative to stem this tsunami wave. The family physician stands in a unique, critical, and first-line position to be able to offer all 3. Their understanding and implementation of these roles are crucial for success in the battle against HF. This review offers a perspective on the role of family physicians in managing HF.

Author Biography

Grace L. Chua, MD, FRCPC, FACC, Cardiologist, Mackenzie Health, Maple, Ontario, Canada

Dr. Grace Chua is a community cardiologist at Mackenzie Health in Richmond Hill and Vaughan, Ontario. Her medical and cardiology training included a fellowship in Adult Echocardiography as well as Clinical Epidemiology at the University of Toronto. She was the Chief of the Division of Cardiology at Mackenzie Health from 2003-2017 and was the initiating force in the development of the hospital’s rapid access cardiology clinic and heart function service. Currently, her passions lie in clinical education and knowledge translation, particularly in the field of heart failure, as well as prevention of cardiometabolic disease. She has been involved in the development and delivery of many educational programs in different formats, both locally and nationally.

References

Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Eur J Heart Fail. 2021; 23:352-380. doi:10.1016/j.cardfail.2021.01.022

Bozkurt, B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023; 29(1):1412-1451. doi:10.1016/j.cardfail.2023.07.006

Canadian Chronic Disease Surveillance System (CCDSS) [Date modified: 2024 March 20]. Public Health Agency of Canada, Health Infobase https://health-infobase.canada.ca.

Moghaddam N, Lindsay P, Hawkins NM, Anderson K, Ducharme A, Lee, DS, et al. Access to heart failure services in Canada: findings of the Heart and Stroke National Heart Failure Resources and Services Inventory. Can J Cardiol. 2023;39(10):1469-1479. doi:10.1016/j.cjca.2023.06.430

Poon S, Leis B, Lambert L, MacFarlane K, Anderson K, Blais C, et al. The state of heart failure care in Canada: minimal improvement in readmissions over time despite an increased number of evidence-based therapies. CJC Open. 2022;4: 667-675. doi:10.1016/j.cjco.2022.04.011

Heart and Stroke Foundation. Falling Short: How Canada is Failing People with Heart Failure—and How We Can Change That. https;//heartstroke.ca/-/media/pdf-files/canada/2022-heart-month/hs-heart-failure-report-2022-final.pdf.

Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019; 21(11):1306-1325. doi:10.1002/ejhf.1594

Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline and reduced ejection fraction 5-year outcomes. J Am Coll Cardiol. 2017;70:2476-2486. doi:10.1016/j.jacc.2017.08.074

Yeung DF, Boom NK, Guo H, Lee DS, Schultz SE, Tu JV. Trends in incidence of outcomes of heart failure in Ontario, Canada:1997 to 2007. CMAJ. 2012;184 (14):765-773. doi:10.1503/cmaj.111958

Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260-266. doi:10.1016/j.ahj.2007.01.041

Blecker S, Kunihiro M, Kottgen A, Loehr LR, Bertoni AG, Boulware LE, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011; 58(1):47-55. doi:10.1053/j.ajkd.2011.02.391

Tao J, Sang D, Zhen L, Zhang X, Li Y, Wang G, et al. Elevated urine albumin-to-creatinine ration increases the risk of new-onset heart failure in patients with type 2 diabetes. Cardiovasc Diabetol. 2023;22(1):70. doi:10.1186/s12933-023-01796-6

Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009;374 9689):543-550. doi:10.1016/S0140-6736(09)61378-7

Mueller C, McDonald K, de Boer, RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-731. doi:10.1002/ejhf.1494

Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RRJ, Lainchbury JG, Richards AM, Ordonez-Llanos J, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med. 2007;167(4):400-407. doi:10.1001/archinte.167.4.400

Tilson L, Tallon E, O’Connell E, Maurer B, Gallagher J, Murtagh G, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66-74. doi:10.1001/jama.2013.7588

Huelsmann, M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62(15):1365-1372. doi:10.1016/j.jacc.2013.05.069

Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017;33(11):1342-1433. doi:10.1016/j.cjca.2017.08.022

Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction (GUIDE-IT). JAMA. 2017;318(8):713-720. doi:10.1001/jama.2017.10565

McLellan J, Bankhead CR, Oke JL, Hobbs FDR, Taylor CJ, Perera R. Natriuretic peptide-guided treatment for heart failure: a systematic review and meta-analysis. BMJ Evid Based Med. 2020; 5(1):33-37. doi:10.1136/bmjebm-2019-111208

McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz J, Giannetti N, et al. CCS/CHFS Heart Failure Guidelines Update: defining a new pharmacologic standard of care of heart failure with reduced ejection fraction. Canadian J Cardiol. 2021;37(4):531-546. doi:10.1016/j.cjca.2021.01.017

McDonagh TA, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36): 3599-3726. doi: 10.1093/eurheartj/ehab368. [published correction appears in Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670]. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022145:e895-e1032. doi: 10.1161/CIR.0000000000001073] [published correction appears in Circulation. 2022 Sep 27;146(13):e185. doi: 10.1161/CIR.0000000000001097] [published correction appears in Circulation. 2023 Apr 4;147(14):e674. doi: 10.1161/CIR.0000000000001142]. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063

McMurray JJV, Packer MP. How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine. Circulation. 2021;143(9):875-877. doi:10.1161/CIRCULATIONAHA.120.052926

Greene SJ, Bulter J, Fonarow GC. Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure—optimizing therapy with the need for speed. JAMA Cardiol. 2021;6(7):743-744. doi:10.1001/jamacardio.2021.0496

Bassi, NS, Ziaeian B, Yancy CW, Fonarow GC. Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol. 2020; 5(8): 948-951. doi:10.1001/jamacardio.2020.0898

Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. [published correction appears in N Engl J Med. 2019 Mar 14;380(11):1090. doi: 10.1056/NEJMx190009]. N Engl J Med. 2019;380(6):539-548. doi:10.1056/NEJMoa1812851

DeVore AD, Braunwald E, Morrow DA, Duffy CI, Amrosy AP, Chakraborty H, et al. Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure; secondary analysis of the open-label extension of the PIONEER-HF trial. JAMA Cardiol. 2020;5(2):202-207. doi:10.1001/jamacardio.2019.4665

Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patents hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1

Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies of acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022; 400(10367):1938-1952. doi:10.1016/S0140-6736(22)02076-1

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. [published correction appears in Eur Heart J. 2024 Jan 1;45(1):53. doi: 10.1093/eurheartj/ehad613]. Eur Heart J. 2023;44(37):3627-3639. doi:10.1093/eurheartj/ehad195

Halliday BP, Wassall R, Lata AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open label, pilot, randomised trial. Lancet. 2019;393:61-73. doi:10.1016/S0140-6736(18)32484-X

Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963

Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390:1394-1407. doi:10.1056/NEJMoa2313917

Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Cioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee APW, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P. NEJM September 1, 2024 DOI: 10.1056/NEJMoa2407107

Petrie M, Borlaug B, Buckholtz K, Ducharme A, Hvelplund A, Lam CSP, et al. HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. Journal of Cardiac Failure. 2024;30(1) P126. https://doi.org/10.1016/j.cardfail.2023.10.024

The Family Physician’s Unique Role in Heart Failure Management

Authors

DOI:

Abstract

Author Biography

Grace L. Chua, MD, FRCPC, FACC, Cardiologist, Mackenzie Health, Maple, Ontario, Canada

References

Downloads

Published

How to Cite

Issue

Section

License

Summary

Open Access

Licence